Subcutaneous Pertuzumab/Trastuzumab/Hyaluronidase-zzxf Approved for HER2-Positive Breast Cancer

The FDA has approved a subcutaneous injection of pertuzumab/trastuzumab/hyaluronidase-zzxf (Phesgo®, Genentech, Inc.) for adults with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This fixed-dose combination treatment is approved in combination with chemotherapy as neoadjuvant therapy for patients who have locally advanced, inflammatory, or early stage (either greater than 2 cm in diameter or node positive) disease; as adjuvant treatment for patients with HER2-positive ...
Continue reading

Metronomic Capecitabine Maintenance for TNBC: Zhongyu Yuan, MD

Metronomic capecitabine maintenance therapy has been shown to be more effective compared with observation for patients with triple-negative breast cancer (TNBC), according to a study led by Zhongyu Yuan, MD. Results of the study have been presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. In this interview with i3 Health, Dr. Yuan shares insights on treating TNBC and future directions in the TNBC treatment landscape. What are the most challenging aspec...
Continue reading

TNBC: Metronomic Capecitabine Maintenance Improves Outcomes

Metronomic capecitabine maintenance after standard treatment has been shown to be a successful therapy for patients with triple-negative breast cancer (TNBC) in a recent study. Results of this study will be reported on later this week in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. Relapse and unfavorable outcomes are still issues among patients with TNBC. According to lead study author XI Wang, MD of the Department of Breast Oncology at Sun Yat-Sen Universit...
Continue reading

Tucatinib for HER2-Positive Metastatic Breast Cancer: Eric P. Winer, MD

In this interview with i3 Health, Eric P. Winer, MD, discusses tucatinib (TukysaTM, Seattle Genetics), recently approved by the FDA in combination with trastuzumab and capecitabine for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least one anti-HER2­–based regimen in the metastatic setting. Dr. Winer, principal investigator of the phase 3 HER2CLIMB trial, on which the approval was based, discusses tucat...
Continue reading

Pyrotinib/Capecitabine Effective for HER2-Positive Metastatic Breast Cancer

Pyrotinib, an irreversible pan-ErbB inhibitor, provides an effective treatment option in combination with capecitabine for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, according to results of a phase 3 trial to be presented later this month in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The open-label, multicenter PHOEBE trial enrolled patients with HER2-positive metastatic breast cancer following treatment...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.